LIFE SCIENCE

We invest in early-stage companies, founded on innovative research-based technologies within pharma and medtech, with compelling value propositions serving unmet medical needs. We look for well-defined development plans with clear value inflection points, enabling robust returns on investment. 

CLEAN TECH ENERGY AND TECHNOLOGY

We invest in leading early stage science and technology based companies with technologies that can make the world a better place and accelerate the transition to a 100% renewable energy system. We look for exceptional entrepreneurs and breakthrough innovations that may have an disruptive impact on industries and markets and create value for individuals, society, industry and investors. 

Sarsia Seed is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy / technology and biotechnology / life science sectors.

Prophylix enters manufacture agreement

Prophylix AS has entered a manufacturing collaboration with Emergent BioSolutions Inc. (NYSE:EBS) whereby Emergent will manufacture Prophylix’s developmental drug NAITgam [Human Platelet Antigen 1a Immunoglobulin (anti-HPA-1a)]. The collaboration will leverage...

SonoClear publishes clinical data

SonoClear publishes clinical data Bergen, May 23, 2019 In a newly published paper in Acta Neurologica the scientists behind the invention of the new acoustic coupling fluid (ACF) for intrasurgical application of ultrasound during neurosurgery publish very promising...

BerGenBio to present new NSCLC and AML clinical data and biomarker data

BerGenBio  to present new NSCLC and AMLclinical data and biomarker data from phase II development programme with selective AXL inhibitor Bemcentinib at ASCO2019 Bergen, May 23, 2019 BerGenBio notes the publication of abstracts relating to new interim clinical and...

SonoCelar secures NOK 10 mill

SonoClear secures MNOK 10 Bergen, May 16, 2019 SonoClear has just secured NOK 10mill (€ 1,1mill) from existing and new investors. The main investors in this round were, Sarsia Seed Fund II, Sintef Venture IV, Co-Founder and Sparebank1 Midt-Norge. The funding will be...

Sarsia Seed Fund II raises NOK 130 mill (€ 14 mill) in second closing.

Sarsia Seed Fund II raises NOK 130 mill (¢ 14 mill) in second closing Bergen, April 23, 2019 This second closing has raised NOK 130 million bringing the total fund capital to just over NOK 430 millioner. KLP and Nysnø are the largest investors in this round. Other...

Vaccibody reports positive results from phase IIa clinical study

Vaccibody reports positive results from phase IIa clinical study Oslo, March 25, 2019 Vaccibody AS today announced positive 12-month results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa...

BerGenBio dispute resolved

BerGenBio dispute resolved February 28. 2019 BerGenBio ASA (OSE:BGBIO) has informed that the six months long arbitration with Rigel regarding the licensing agreement has been resolved. This news and the content of the settlement is very positive for the Bergen based...

Vaccibody to present 4 poster during AACR

Vaccibody to present 4 poster during AACR Vaccibody AS has been accepted for an impressive 4 poster presentations at the annual meeting in the American Association for Cancer Research in April 2019. Two of the papers demonstrates the progress made with the unique...

Vaccibody secures NOK 230 million (EUR 23,6 million)

Vaccibody secures NOK 230 million (EUR 23,6 million) The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s...